查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798780

全球足底筋膜炎治療市場成長、規模和趨勢分析：按治療類型、適應症、最終用戶和地區的展望、競爭策略、預測（至2034年）

Global Plantar Fasciitis Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 242 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到2034年全球足底筋膜炎治療市場規模將達到 32.7億美元，年複合成長率為 9.57%。

足底筋膜炎的治療包括多種療法，目的是緩解症狀並解決根本病因。足底筋膜炎是一種常見的足部疾病，其特徵是足底筋膜（一條沿著足底從跟骨延伸至足趾的厚組織帶）的發炎和刺激。

阻礙因素：足底筋膜炎治療市場擴張的因素包括衝擊波療法和手術等先進治療方法費用高昂，對經濟條件較差地區的患者可能造成負擔。此外，大眾對足底筋膜炎及其治療方法缺乏認知，也是市場擴張的一大障礙。

本報告調查了全球足底筋膜炎治療市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 引言

第2章 調查方法

第3章 執行摘要

第4章 市場動態

  • 促進因素、阻礙因素、機會與挑戰分析

第5章 市場變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭態勢

  • 製造地、銷售區域、產品類型分佈
  • 併購、合作夥伴關係、產品發布和合作

第7章 全球足底筋膜炎治療市場（依治療類型）

  • 治療方法
    • 矯正器具
    • 衝擊波療法
    • 超音波治療
    • 其他
  • 藥物治療
    • 非類固醇消炎劑（NSAID）
    • 皮質類固醇注射
    • 局部止痛藥
  • 外科手術
    • 足底筋膜切開術
    • 腓腸肌（小腿腹部）延長
    • 肌腱轉移

第8章 全球足底筋膜炎治療市場（依適應症）

  • 輕度
  • 中度
  • 重度

第9章 全球足底筋膜炎治療市場（依最終用戶）

  • 醫院
  • 整形外科診所
  • 物理治療中心
  • 其他

第10章 全球足底筋膜炎治療市場

  • 全球市場規模和市場佔有率

第11章 全球足底筋膜炎治療市場（依地區）

  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亞
    • 其他
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他

第12章 公司簡介

  • 3M
  • Algeo Ltd
  • Bauerfeind USA Inc
  • Hanger, Inc
  • OrthoBethesda
  • OrthoMed, Inc
  • Ottobock
  • Pfizer, Inc
  • Revance Therapeutics, Inc
  • Sanofi
  • 其他

第13章 結論

第14章 簡稱列表

第15章 參考鏈接

簡介目錄
Product Code: HLCA25223

Plantar Fasciitis Treatment Market Introduction and Overview

According to SPER market research, 'Global Plantar Fasciitis Treatment Market Size- By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Plantar Fasciitis Treatment Market is predicted to reach 3.27 billion by 2034 with a CAGR of 9.57%.

Plantar fasciitis treatment encompasses a range of therapeutic approaches aimed at relieving symptoms and addressing the root causes of plantar fasciitis, which is a prevalent foot condition marked by inflammation and irritation of the plantar fascia. This thick band of tissue extends along the foot's base, connecting the heel bone to the toes.

Restraints: Factors impeding the treatment market for plantar fasciitis involve the substantial expense associated with advanced therapies, including shock wave therapy and surgical options, which may be financially daunting for certain patients, particularly in economically disadvantaged areas. Furthermore, the insufficient awareness regarding plantar fasciitis and its corresponding treatments among various individuals is obstructing market expansion.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Indication, By End-User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered 3M, A. Algeo Ltd, Bauerfeind USA Inc, Hanger, Inc, OrthoBethesda, OrthoMed, Inc, Ottobock, Pfizer, Inc, Revance Therapeutics, Inc, Sanofi.

Global Plantar Fasciitis Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Plantar Fasciitis Treatment Market is segmented as; Therapy, Medication Therapy, Surgery.

By Indication: Based on the Indication, Global Plantar Fasciitis Treatment Market is segmented as; Mild, Moderate, Severe.

By End-User: Based on the End-User, Global Plantar Fasciitis Treatment Market is segmented as; Hospitals, Orthopedic Clinics, Physiotherapy Centers, Other End-User.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPERs internal database
    • 2.1.4. Premium insight from KOLs
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTERs Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Plantar Fasciitis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plantar Fasciitis Treatment Market

7. Global Plantar Fasciitis Treatment Market, By Treatment Type (USD Million) 2021-2034

  • 7.1. Therapy
    • 7.1.1. Orthotic devices
    • 7.1.2. Shockwave therapy
    • 7.1.3. Ultrasound therapy
    • 7.1.4. Other therapies
  • 7.2. Medication Therapy
    • 7.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • 7.2.2. Corticosteroid injections
    • 7.2.3. Topical pain relievers
  • 7.3. Surgery
    • 7.3.1. Plantar fascia release
    • 7.3.2. Gastrocnemius recession
    • 7.3.3. Tendon transfer

8. Global Plantar Fasciitis Treatment Market, By Indication (USD Million) 2021-2034

  • 8.1. Mild
  • 8.2. Moderate
  • 8.3. Severe

9. Global Plantar Fasciitis Treatment Market, By End-User (USD Million) 2021-2034

  • 9.1. Hospitals
  • 9.2. Orthopedic Clinics
  • 9.3. Physiotherapy Centers
  • 9.4. Other End-User

10. Global Plantar Fasciitis Treatment Market, (USD Million) 2021-2034

  • 10.1. Global Plantar Fasciitis Treatment Market Size and Market Share

11. Global Plantar Fasciitis Treatment Market, By Region, (USD Million) 2021-2034

  • 11.1. Asia-Pacific
    • 11.1.1. Australia
    • 11.1.2. China
    • 11.1.3. India
    • 11.1.4. Japan
    • 11.1.5. South Korea
    • 11.1.6. Rest of Asia-Pacific
  • 11.2. Europe
    • 11.2.1. France
    • 11.2.2. Germany
    • 11.2.3. Italy
    • 11.2.4. Spain
    • 11.2.5. United Kingdom
    • 11.2.6. Rest of Europe
  • 11.3. Middle East and Africa
    • 11.3.1. Kingdom of Saudi Arabia
    • 11.3.2. United Arab Emirates
    • 11.3.3. Qatar
    • 11.3.4. South Africa
    • 11.3.5. Egypt
    • 11.3.6. Morocco
    • 11.3.7. Nigeria
    • 11.3.8. Rest of Middle-East and Africa
  • 11.4. North America
    • 11.4.1. Canada
    • 11.4.2. Mexico
    • 11.4.3. United States
  • 11.5. Latin America
    • 11.5.1. Argentina
    • 11.5.2. Brazil
    • 11.5.3. Rest of Latin America

12. Company Profile

  • 12.1. 3M
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Algeo Ltd
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. Bauerfeind USA Inc
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Hanger, Inc
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. OrthoBethesda
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. OrthoMed, Inc
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. Ottobock
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Pfizer, Inc
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Revance Therapeutics, Inc
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Sanofi
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Others

13. Conclusion

14. List of Abbreviations

15. Reference Links